OLT1177 (dapansutrile) is an orally active specific NLRP3 inhibitor which has been studied in gout and HF.121, 122, 123 A randomized controlled trial testing the safety and efficacy of dapansutrile in moderate COVID-19 (NCT04540120) is currently ongoing and results are expected. Here, NLRP3 is linked to COVID-19.